Search Within

Sergio Andres Giralt

  1. "The Lancet Haematology"
Formats
  1. Journal Article (5)
Groups
  1. Bone Marrow Transplant (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Hematologic Malignancies, Division of (5)
  5. Survivorship Research (3)
  6. CTCR Scholars (2)

More Groups

People
  1. Hani Hassoun (2)
  2. Heather Landau (2)
  3. Ahmet Dogan (1)
  4. Alexander Lesokhin (1)
  5. Andriy Derkach (1)
  6. Ann Jakubowski (1)

More People

Years
  1. 2024 (1)
  2. 2021 (2)
  3. 2019 (1)
  4. 2017 (1)
Publications
  1. The Lancet Haematology (5)
Publishers
  1. Elsevier Science, Inc. (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Development and validation of a disease risk stratification system for patients with haematological malignancies: A retrospective cohort study of the European Society for Blood and Marrow Transplantation registry
    Journal Article

    Shouval, R.; Fein, J. A.; Labopin, M.; Cho, C.; Bazarbachi, A.; Baron, F.; Bug, G.; Ciceri, F.; Corbacioglu, S.; Galimard, J. E.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: A randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
    Journal Article

    Bolaños-Meade, J.; Reshef, R.; Fraser, R.; Fei, M.; Abhyankar, S.; Al-Kadhimi, Z.; Alousi, A. M.; Antin, J. H.; Arai, S.; Bickett, K.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial
    Journal Article

    Holstein, S. A.; Jung, S. H.; Richardson, P. G.; Hofmeister, C. C.; Hurd, D. D.; Hassoun, H.; Giralt, S.; Stadtmauer, E. A.; Weisdorf, D. J.; Vij, R.; more...
    The Lancet Haematology (2017)

    Fulltext@MSK | Save